IMNN news

Latest 2 stories · newest Nov 5, 2026

IMNN
IMMU Provides Corporate Updates and Revenue Guidance for Full Year 2025

Immunic, Inc. provided guidance that implies flat revenue for fiscal year 2025 and announced that it has not yet commenced clinical trials for its antibody pipeline.

IMNN
Imunon sells rights to ThermoDox to VoxelDox

Imunon is divesting ThermoDox rights to VoxelDox for up to $16.5 million and royalties to fund its core IMNN-001 program, reinforcing capital allocation strategy.

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same IMNN feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/IMNN/newsSTART FREE